Premium
Type‐II estrogen binding sites in a lymphoblastoid cell line and growth‐inhibitory effect of estrogen, anti‐estrogen and bioflavonoids
Author(s) -
Scambia Giovanni,
Ranelletti Franco O.,
Panici Pierluigi Benedetti,
Piantelli Mauro,
Rumi Carlo,
Battaglia Francesco,
Larocca Luigi M.,
Capelli Amaldo,
Mancuso Salvatore
Publication year - 1990
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910460627
Subject(s) - estrogen , inhibitory postsynaptic potential , lymphoblast , endocrinology , medicine , cell culture , chemistry , biology , genetics
Type‐II estrogen‐binding sites (type‐II EBS) have been demonstrated in the human lymphoblastoid cell line IM‐9 using a whole‐cell assay with (6, 7‐ 3 H) estradiol ( 3 H‐E 2 ) as tracer. Competition analysis showed that the anti‐estrogen tamoxifen and the flavonoids quercetin and rutin competed for ( 3 H)‐E 2 binding to type‐II EBS. Growth experiments demonstrated that diethylstilbestrol (DES) tamoxifen (TAM), quercetin and rutin exerted a reversible dose‐dependent inhibition of cell proliferation in the range of concentrations between 10 nM and 10 μM. The relative binding affinity of quercetin, rutin, DES and TAM for type‐II EBS correlated well with their potency as cell growth inhibitors. Moreover, hesperidin, a flavonoid which does not bind to type‐II EBS, was ineffective in inhibiting cell growth. Cell‐cycle analysis showed that the growth‐inhibitory effect of DES, TAM or quercetin was due to a blocking effect in the G 0 ‐G 1 phases. Our results suggest that high estrogen and anti‐estrogen concentrations and flavonoids may regulate IM‐9 cell growth through a common mechanism involving a binding interaction with type‐II EBS.